Arti BaliNew Delhi, Jan. 29 -- India's pharmaceutical industry has urged the government to implement sweeping direct tax reforms in the union Budget 2026-27, emphasising the need for stronger incentives for research and development (R&D), domestic API manufacturing, and simplified compliance to improve the ease of doing business.
With Finance Minister Nirmala Sitharaman set to present the Budget on February 1, industry stakeholders are closely watching policy measures that could shape the future of India's manufacturing and infrastructure sectors.
In pre-Budget recommendations submitted to the Finance Ministry, the Indian Drug Manufacturers' Association (IDMA) called for restoring tax incentives for in-house research, easing compliance bu...